Towards patient centricity: Pfizer

In a new series Amanda Barrell looks at how different companies are turning patient centricity into a reality.

2nd RNA Targeted Drug Discovery Summit

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 

GlycoMimetics craters as Pfizer says rivipansel flunks trial

Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.

J&J faces FTC probe on Remicade biosimilar defence

Pfizer confirms generic medicines merger with Mylan